Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
在随机 III 期临床试验 (SWOG S0421) 中，接受多西他赛和阿曲生坦治疗的转移性去势抵抗性前列腺癌患者与接受多西他赛和安慰剂治疗的患者报告结局
期刊:Journal of Patient-Reported Outcomes
影响因子:2.9
doi:10.1186/s41687-018-0054-5
Unger, Joseph M; Griffin, Katherine; Donaldson, Gary W; Baranowski, Karen M; Good, Margorie J; Reburiano, Eunicia; Hussain, Maha; Monk, Paul J; Van Veldhuizen, Peter J; Carducci, Michael A; Higano, Celestia S; Lara, Primo N; Tangen, Catherine M; Quinn, David I; Wade, James L III; Vogelzang, Nicholas J; Thompson, Ian M Jr; Moinpour, Carol M
